#United States #Berwyn #Nordic Pharma #Harrow #Maxitrol

Nordic Pharma Announces Authorized Generic of Maxitrol

In a significant move for the eyecare industry, Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has revealed its collaboration with Harrow (Nasdaq: HROW), a prominent North American eyecare company. Together, they are set to introduce an authorized generic version of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension). This product serves an essential role in treating bacterial eye infections, marking an exciting development in pharmaceutical offerings.

A Strategic Move in Eye Care

The official announcement, made on April 24, 2025, has been met with enthusiasm as it promises to provide patients with an affordable prescription option for managing eye health. According to recent market data by IQVIA, Maxitrol and its generic counterparts achieved substantial annual sales of $20.8 million in the U.S. as of January 2025. This statistic highlights the existing demand and the vital nature of this medication in the ophthalmic market.

“Today signifies the end of months of effort to release this authorized generic into the market. This product enhances our generic portfolio, providing patients with another cost-effective option,” stated Thomas Sammler, VP of Commercial Operations at Nordic Pharma. His words resonate with the company’s mission to ensure that vital medication remains within reach for those who need it.

About Nordic Group B.V.

Nordic Group B.V. is a privately held international pharmaceutical entity, recognized for developing and commercializing specialized products. The company has strategically expanded its portfolio through focused acquisitions and development efforts, particularly within the eye care sector, rheumatology, and women’s health. Over the years, Nordic Group has cultivated deep-rooted connections throughout Europe while recently extending its reach globally through multiple acquisitions.

As part of SEVER Life Sciences, established in 2019, Nordic Group collaborates with diverse companies to deliver a wide array of products and pharmaceutical development services, greatly benefiting patient access to vital medications.

Insights into Nordic Pharma, Inc.

Nordic Pharma, Inc. has positioned itself as a notable player in the eyecare market through its partnerships with well-respected global biopharmaceutical companies. The company specializes in bringing biotechnology-derived medicines and utilizing sterile manufacturing processes along with state-of-the-art technologies to market.

Their collaboration with Harrow not only emphasizes their commitment to eye health but also highlights their innovative approaches to pharmaceutical development.

Harrow: A Leader in Eyecare Products

Harrow, Inc. is renowned for its dedication to eyecare, focusing on the discovery and commercialization of groundbreaking ophthalmic pharmaceuticals in the North American region. By making its range of eyecare products more accessible and affordable, Harrow contributes significantly to the preservation of vision for millions of patients yearly.

For those seeking further information about Nordic Pharma, Inc. or their product offerings, please visit www.nordicpharmausa.com.

Looking Ahead

The launch of this authorized generic version of Maxitrol reflects a broader commitment within the pharmaceutical industry to make effective treatments more accessible. With rising pharmaceutical costs becoming a pressing issue, such partnerships hint at a promising direction for future collaborations designed to improve patient care in eyecare and beyond.

In conclusion, this announcement signifies not just a product launch but also a step toward more affordable eyecare solutions that can further enhance patient well-being across North America.